Loading organizations...
Ena Respiratory is a clinical-stage pharmaceutical company based in Melbourne, Australia, that develops antiviral host defense enhancers to prevent respiratory viral infections such as COVID-19, influenza, and RSV. The biotechnology firm focuses on virus-agnostic intranasal immunomodulators, specifically its lead candidate INNA-051, which is designed to boost innate immunity at the primary site of infection for vulnerable populations. The enterprise is currently advancing this candidate through clinical trials, with a Phase II study planned for the upcoming 2025 to 2026 US respiratory season. To support its clinical development, the company has secured up to AU$32 million in Series A funding backed by lead investors Brandon Capital Partners, the Minderoo Foundation, and Uniseed. Additionally, the organization was awarded a $4.38 million agreement from the US Department of Defense for manufacturing. Ena Respiratory was founded in 2020 by Christophe Demaison.
Ena Respiratory has raised $106.9M across 6 funding rounds.
Ena Respiratory has raised $106.9M in total across 6 funding rounds.
Ena Respiratory has raised $106.9M across 6 funding rounds. Most recently, it raised $22.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $22M Series B | — | Brandon Capital Partners, Bill & Melinda Gates Foundation, Chris Smith, FLU LAB, Stoic VC, Uniseed | Announced |
| Jun 15, 2021 | $24.7M Venture Round | Brandon Capital, Minderoo Foundation | Uniseed | Announced |
| Jun 1, 2021 | $24M Series U | — | Brandon Capital Partners | Announced |
| Sep 1, 2020 | $8M Series A | — | Brandon Capital Partners | Announced |
| Oct 8, 2018 | $23.3M Series A | — | Brandon Capital, Minderoo Foundation, Uniseed | Announced |
| May 1, 2017 | $5M Series U | — | Brandon Capital Partners | Announced |
Ena Respiratory has raised $106.9M in total across 6 funding rounds.
Ena Respiratory's investors include Brandon Capital Partners, Bill & Melinda Gates Foundation, Chris Smith, Flu Lab, Stoic VC, Uniseed, Brandon Capital, Minderoo Foundation.
ENA Respiratory is a clinical-stage pharmaceutical company developing intranasal antiviral host defense enhancers to prevent severe complications from respiratory viral infections in at-risk populations, such as those with COPD.[1][2][3] Its lead product, INNA-051, is a virus-agnostic toll-like receptor 2/6 (TLR2/6) agonist that primes the innate immune response, accelerating viral clearance and boosting antiviral defenses like IFN Type I & III, as shown in a Phase IIa influenza-challenge study.[1][3] The company serves the healthcare sector, targeting vulnerable groups with self-administered nasal prophylactics effective against diverse viruses including SARS-CoV-2, rhinovirus, H1N1, and influenza strains; it has raised US$26M (AU$44M) from investors like Brandon Capital, The Minderoo Foundation, and Uniseed, plus a US$13.1M U.S. Department of Defense contract.[1][3]
Growth momentum includes FDA IND clearance for an improved dry powder formulation of INNA-051, partnerships with the U.S. COPD Foundation, and selection for BLUE KNIGHT™ (a Johnson & Johnson Innovation and BARDA initiative for pandemic solutions).[3][6] Formerly Innavac, ENA operates from Melbourne, Australia, positioning itself as complementary to vaccines and antivirals with a safe profile for seasonal use.[1][2]
Founded in 2020 in Melbourne, Australia, as Innavac (later rebranded ENA Respiratory), the company emerged from early research aimed at boosting the immune system against respiratory infection complications.[1][4] The breakthrough for lead candidate INNA-051 stemmed from a serendipitous "accident" in preclinical work—a chance discovery during experiments that was refined based on researcher Roberto's feedback, shifting focus to innate immune modulation.[4] The COVID-19 pandemic provided pivotal momentum, heightening virology awareness and enabling recruitment for larger Phase IIa trials that validated INNA-051's efficacy in an influenza-challenge model.[1][3][4]
Key early traction came from equity funding (totaling AU$49M including later rounds) and strategic pivots, such as enhancing investor appeal and securing U.S. Department of Defense contracts amid global respiratory health focus.[3][4] This "luck" was harnessed through adaptive strategy, evolving from basic immune enhancement to virus-agnostic nasal prophylactics.[4]
ENA Respiratory rides the post-pandemic wave in respiratory health innovation, capitalizing on heightened awareness of viral sequelae in vulnerable groups like COPD patients amid ongoing threats from influenza, COVID-19 variants, and emerging pathogens.[1][4][6] Timing is ideal: clinical successes during COVID enabled scaled trials, while market forces like aging populations, rising antiviral resistance, and demand for non-vaccine prophylactics favor virus-agnostic solutions.[2][3] It influences the ecosystem by pioneering host-directed therapies via BLUE KNIGHT™ and DoD partnerships, potentially setting standards for innate immune boosters in pandemic preparedness.[3][6]
Next steps include advancing the dry-powder INNA-051 into further trials for COPD and prophylaxis, leveraging DoD contracts and BLUE KNIGHT™ for rapid scaling toward approval.[3][6] Trends like recurrent viral waves and biotech focus on immune modulation will propel growth, with potential expansion to broader at-risk uses if Phase IIb/III data confirm broad efficacy.[1][4] ENA's influence may evolve from niche innovator to key player in respiratory defense, transforming prevention for millions—echoing its origins in serendipitous discovery now primed for global impact.[4]
